Compare Danaher Corporation (DHR) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Matson Inc — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while Matson Inc trades at $214.45 (market cap $6.11B). The key difference: Danaher Corporation is far larger — about 23.9× Matson Inc's market cap, and Danaher Corporation pays the higher dividend (0.77%). Which is the better fit depends on your goals.
| DHR | MATX | |
|---|---|---|
Market Cap | $145.83B | $6.11B |
Sector | Health | Technology |
52-Week High | $242.05 | $223.55 |
52-Week Low | $161.91 | $88.05 |
Enterprise Value | $168.04B | $6.71B |
Dividend Yield | 0.77% | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $207.44, down 0.87% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company demonstrates solid fundamentals with consistent earnings beats in recent quarters and a healthy 15.95% net income margin. Recent developments include the Masimo acquisition approval and new product launches in the SCIEX division, supporting growth prospects in biotechnology and life sciences segments.
DHR presents a mixed outlook with strong analyst support (69% buy ratings) but faces valuation concerns at a P/E of 36.98. Key opportunities include biotechnology segment growth and strategic acquisitions, while risks involve elevated valuation, competitive pressures, and potential market volatility. The stock trades above the consensus price target of $202.33, suggesting limited near-term upside despite positive fundamentals.
Matson (MATX) trades at $214.45, up 2.76% with strong earnings momentum after beating Q2 2026 EPS estimates of $3.79 with $4.27 actual. The stock shows bullish technical signals with support at $200 and resistance at $209. Fundamentally, the company maintains solid profitability with 13.41% net margin and 17.21% ROE, supported by raised full-year guidance after strong Q2 results.
MATX presents a compelling investment case with 27.3% upside to consensus price target of $265, supported by 66.7% analyst buy ratings. Key risks include exposure to Trans-Pacific trade volatility and competitive shipping markets, but resilient consumer demand and premium China service position the company for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
